1. Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission 
Julie M Vose, Douglas J Rizzo, Jing Tao-Wu, James O Armitage, Asad Bashey, Linda J Burns, Neal Paul Christiansen, Cesar O Freytes, Robert Peter Gale, John Gibson, Sergio A Giralt, Roger H Herzig, Charles F Lemaistre, Philip L McCarthy, Stephen D Nimer, Finn B Petersen, David P Schenkein, Peter H Wiernik, Joseph M Wiley, Fausto R Loberiza, Hillard M Lazarus, Koen van Biesen, Mary M Horowitz 
Biology of Blood and Marrow Transplantation 
Volume 10, Issue 2, Pages (February 2004)
DOI: /j.bbmt

2. Figure 1
Probability of overall and progression-free survival in patients who underwent transplantation in CR 2 or Rel 1 for diffuse aggressive NHL.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )

3. Figure 2
Probability of progression-free survival by time from diagnosis to relapse before transplantation.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )

4. Figure 3
Probability of progression-free survival by age at the time of transplantation.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )

5. Figure 4
Probability of progression-free survival in patients who received or did not receive myeloid growth factors after transplantation for enhanced myeloid recovery and graft type.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )

6. Figure 5
Probability of relapse in patients who received or did not receive myeloid growth factor after transplantation for enhanced myeloid recovery and graft type.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )